Myasthenia Gravis Induced by Immune Checkpoint Inhibitors - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Journal of Immunotherapy Année : 2019

Myasthenia Gravis Induced by Immune Checkpoint Inhibitors


Immune checkpoint inhibitors deeply improved the prognosis of metastatic melanoma or other types of cancer, but their related adverse effects (AEs) can be very severe, especially when the neurological system is touched, as in myasthenia gravis (MG). It is a rare immune AE that can be life-threatening and can be revealed by several symptoms. We report a case of our experience and review the current literature of MG exacerbated or occurring during immunotherapy to describe characteristics of this AE, warn the oncologist about this toxicity, and summarize the treatments conducted. Thirty-four cases of MG were reported, mostly with anti-programmed cell death protein 1 checkpoint inhibitor, and with melanoma. Onset was quick after the first or second infusion. Treatment comprised corticosteroids, prostigmine, and more or less plasmapheresis or immunoglobulins. Prognosis is poor, as 13 patients died after MG. MG is a rare immune-related AE that must be rapidly evoked and treated in case of neurological symptoms emerging after immunotherapy.
Fichier non déposé

Dates et versions

hal-02619609 , version 1 (25-05-2020)



Ondine Becquart, Julie Lacotte, Pauline Malissart, Jérémy Nadal, Candice Lesage, et al.. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors. Journal of Immunotherapy, 2019, 42 (8), pp.309-312. ⟨10.1097/CJI.0000000000000278⟩. ⟨hal-02619609⟩
42 Consultations
1 Téléchargements



Gmail Facebook X LinkedIn More